Cutiss designed the experiments and supplied the cells; SpacePharma designed the equipment needed to run them aboard the ISS, like boxes that contain the microfluidic chips.

Cutiss, a Swiss clinical-stage life sciences company, develops regenerative medicine and skin tissue engineering therapies. The company’s lead product is a personalized skin graft called denovoSkin.

Marino, the Cutiss CEO, told the Globe that the treatment also aims to reduce scarring for burn victims, which would prevent complications and reduce the need for further reconstructive procedures.

In this Pharmaceutical Executive interview, Daniela Marino, PhD, Co-founder and CEO of CUTISS, talks about her involvement in supporting the development of denovoSkin™, an autologous, bio-engineered ...

Dr Daniela Marino is the CEO and co-founder of skin-graft innovators Cutiss and one of the inspirational leaders that UBS supports and celebrates through its Global Visionaries programme. Marino is ...

The Key Burns Companies in the market include - Kerecis, Mallinckrodt Pharmaceuticals, Skingenix, RenovaCare, CUTISS AG, Argle Therapeutics, Medline Industries, Amryt ...

The recently created UZH Life Sciences Fund is making its first investment, putting one million CHF into CUTISS, a young company aiming to bring bioengineered skin grafts to market. The fund will ...